Moderna Shares Surge After Hantavirus Case Draws Market Attention
Shares of Moderna jumped nearly 8% in premarket trading on Monday after reports emerged that a U.S. national tested positive for the Andes strain of hantavirus.
The news renewed investor interest in Moderna’s early-stage efforts to develop potential treatments targeting hantavirus infections and other emerging diseases.
By 05:38 ET, Moderna stock was trading approximately 7.7% higher in premarket activity.
U.S. Health Officials Confirm Hantavirus Cases
According to the U.S. Department of Health and Human Services (HHS), one passenger aboard a repatriation flight tested mildly positive for the virus, while another individual displayed mild symptoms.
The passengers were among 17 American citizens evacuated from the MV Hondius cruise ship and transported back to the United States.
Health officials stated that the two potentially infected individuals were transported in specialized aircraft biocontainment units as a precautionary measure.
Moderna Expanding Research Into Hantavirus Treatments
Moderna confirmed last week that it is actively researching a potential hantavirus treatment, although the company described the program as still being in its early stages.
The biotech company said the project forms part of its broader strategy to address emerging infectious diseases using its mRNA technology platform.
Back in 2023, Moderna signed a research partnership agreement with Korea University to develop a hantavirus vaccine through the company’s mRNA Access Program.
No Approved Hantavirus Vaccine Currently Exists
At present, there are no approved vaccines or targeted antiviral treatments specifically designed for hantavirus infections.
Current medical care mainly focuses on supportive treatment to stabilize patients while the body fights the infection naturally.
Carlos del Rio emphasized the importance of continued research, stating that vaccine and treatment development efforts are urgently needed.
Andes Virus Raises Additional Concerns
The strain identified in the recent cases was the Andes virus, a hantavirus variant primarily found in South America, where the cruise ship originated.
Unlike most hantavirus strains, which typically spread through contact with infected rodent urine, saliva, or feces, the Andes strain is considered one of the few variants capable of limited human-to-human transmission.
Although person-to-person spread remains rare, health authorities continue monitoring the situation closely.
